<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="3657"><DrugName>morphine (oral, sustained-release), Allergan</DrugName><DrugNamesKey><Name id="42766509">Kadian</Name><Name id="42766511">Kapanol</Name><Name id="42766512">Morcap SR</Name><Name id="42937679">morphine</Name><Name id="43075776">morphine sulfate</Name></DrugNamesKey><DrugSynonyms><Name><Value>morphine sulfate anyhdrous</Value></Name><Name><Value>(-)-morphine</Value></Name><Name><Value>Kadian</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>PF-402</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Kapanol</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Morcap SR</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>morphine, Glaxo</Value></Name><Name><Value>morphine, Dainippon</Value></Name><Name><Value>morphine sulfate, Alpharma</Value></Name><Name><Value>morphine (oral, sustained-release), Alpharma</Value></Name><Name><Value>morphine (oral, sustained-release), Allergan</Value></Name><Name><Value>morphine</Value><Types><Type>BANN</Type></Types></Name><Name><Value>morphine (oral, sustained-release), Actavis</Value></Name><Name><Value>morphine sulfate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Slow release oral morphine</Value></Name><Name><Value>64-31-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>57-27-2</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>6211-15-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24920">F H Faulding &amp; Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Company id="1037040">Mayne Pharma Group Ltd</Company><Company id="1088700">Allergan plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1015171">Actavis Group HF</Company><Company id="13601">Abbott Laboratories</Company><Company id="14008">Alpharma Inc</Company><Company id="15138">Bristol-Myers Squibb (Pty) Ltd</Company><Company id="16453">Glaxo Group Ltd</Company><Company id="16969">Zeneca Holdings Inc</Company><Company id="24932">Faulding &amp; Co Ltd</Company><Company id="26660">Sanofi Winthrop Inc</Company><Company id="27069">GlaxoSmithKline Australia</Company><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3657" type="Drug"><TargetEntity id="91342" type="siDrug">Morphine sulfate</TargetEntity></SourceEntity><SourceEntity id="1015171" type="Company"><TargetEntity id="4295872115" type="organizationId">Actavis Group ehf</TargetEntity></SourceEntity><SourceEntity id="1037040" type="Company"><TargetEntity id="4295858866" type="organizationId">Mayne Pharma Group Ltd</TargetEntity></SourceEntity><SourceEntity id="1088700" type="Company"><TargetEntity id="5040050523" type="organizationId">Allergan plc</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="14008" type="Company"><TargetEntity id="4295903324" type="organizationId">Alpharma LLC</TargetEntity></SourceEntity><SourceEntity id="15138" type="Company"><TargetEntity id="5000258701" type="organizationId">Bristol-Myers Squibb (Proprietary) Ltd</TargetEntity></SourceEntity><SourceEntity id="16453" type="Company"><TargetEntity id="5000022355" type="organizationId">Glaxosmithkline Services Unlimited</TargetEntity></SourceEntity><SourceEntity id="16969" type="Company"><TargetEntity id="5000714192" type="organizationId">Zeneca Holdings Inc</TargetEntity></SourceEntity><SourceEntity id="24920" type="Company"><TargetEntity id="4295857399" type="organizationId">Mayne Pharma International Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="24932" type="Company"><TargetEntity id="5035554781" type="organizationId">Faulding and Co Ltd</TargetEntity></SourceEntity><SourceEntity id="26660" type="Company"><TargetEntity id="5036162236" type="organizationId">Sanofi Winthrop Inc</TargetEntity></SourceEntity><SourceEntity id="27069" type="Company"><TargetEntity id="4298145077" type="organizationId">GlaxoSmithKline Investments Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2400" type="ciIndication"><TargetEntity id="R06.02" type="ICD10"></TargetEntity><TargetEntity id="R06.0" type="ICD10"></TargetEntity><TargetEntity id="10013968" type="MEDDRA"></TargetEntity><TargetEntity id="D004417" type="MeSH"></TargetEntity><TargetEntity id="-2091190182" type="omicsDisease"></TargetEntity><TargetEntity id="1523" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="243" type="ciIndication"><TargetEntity id="F11.2" type="ICD10"></TargetEntity><TargetEntity id="D009293" type="MeSH"></TargetEntity><TargetEntity id="-1731206897" type="omicsDisease"></TargetEntity><TargetEntity id="1154" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity><SourceEntity id="PTGT-01361" type="ciTarget"><TargetEntity id="43836512449883" type="siTarget">Mu-type opioid receptor</TargetEntity><TargetEntity id="1032" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Pain - Australia - Aug-1994</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="20">Pain</Indication><Indication id="2400">Dyspnea</Indication><Indication id="243">Opiate dependence</Indication></IndicationsPrimary><ActionsPrimary><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="805">Daily dosing</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-20T04:47:01.000Z</LastModificationDate><ChangeDateLast>2019-05-21T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="24928" linkType="Company"&gt;Faulding&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="30060" linkType="Company"&gt;Mayne&lt;/ulink&gt;), and now marketed by &lt;ulink linkID="1015171" linkType="Company"&gt;Actavis Group&lt;/ulink&gt; (a subsidiary of Watson, subsequently &lt;ulink linkID="21717" linkType="Company"&gt;Actavis Inc&lt;/ulink&gt;, now &lt;ulink linkID="1088700" linkType="Company"&gt;Allergan&lt;/ulink&gt;), Kadian is an oral sustained-release formulation of the opioid morphine, which allows once-daily dosing  [&lt;ulink linkID="1362759" linkType="Reference"&gt;1362759&lt;/ulink&gt;]. The product is indicated for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time [&lt;ulink linkID="660932" linkType="Reference"&gt;660932&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Kadian was first approved and launched in US in 1996 by former licensee &lt;ulink linkID="16967" linkType="Company"&gt;Zeneca&lt;/ulink&gt; (now &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;) [&lt;ulink linkID="213178" linkType="Reference"&gt;213178&lt;/ulink&gt;]. By February 1996,  approval had been granted in the UK and presumably launched shortly following approval  by former licensee &lt;ulink linkID="26660" linkType="Company"&gt;Sanofi Winthrop&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;) [&lt;ulink linkID="200351" linkType="Reference"&gt;200351&lt;/ulink&gt;].    By October 1999, the product had been launched in most EU countries by former licensee &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK) under the trade name Kapanol [&lt;ulink linkID="349169" linkType="Reference"&gt;349169&lt;/ulink&gt;]. The product was launched in Japan in November 1999 by Japanese licensee &lt;ulink linkID="15606" linkType="Company"&gt;Dainippon&lt;/ulink&gt; (now &lt;ulink linkID="1017117" linkType="Company"&gt;Sumitomo Dainippon&lt;/ulink&gt;) [&lt;ulink linkID="349169" linkType="Reference"&gt;349169&lt;/ulink&gt;], [&lt;ulink linkID="352716" linkType="Reference"&gt;352716&lt;/ulink&gt;], [&lt;ulink linkID="393513" linkType="Reference"&gt;393513&lt;/ulink&gt;]. In April 2007, the FDA approved a 10 mg Kadian capsule formulation; at that time, Kadian was available as 10, 20, 30 , 50 , 60, 80, 100 and 200 mg capsules [&lt;ulink linkID="660932" linkType="Reference"&gt;660932&lt;/ulink&gt;], [&lt;ulink linkID="736207" linkType="Reference"&gt;736207&lt;/ulink&gt;], [&lt;ulink linkID="769801" linkType="Reference"&gt;769801&lt;/ulink&gt;], [&lt;ulink linkID="786647" linkType="Reference"&gt;786647&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug has been  developed and launched for other indications including dyspnea [&lt;ulink linkID="1616332" linkType="Reference"&gt;1616332&lt;/ulink&gt;]. In February 2019, the Therapeutic Goods Administration (TGA) has approved Kapanol low dose 10 and 20 mg capsules in Australia, for the treatment of dyspnea (chronic breathlessness) and the drug was presumably launched   [&lt;ulink linkID="2121030" linkType="Reference"&gt;2121030&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug is being developed for the potential treatment of opioid use disorder. In May 2019, a phase III trial was planned to initiate in July 2019 [&lt;ulink linkID="2152266" linkType="Reference"&gt;2152266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Alpharma (subsequently King, now &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt;) also markets &lt;ulink linkID="54244" linkType="Drug"&gt;Embeda&lt;/ulink&gt;, an abuse-resistant formulation of Kadian [&lt;ulink linkID="627651" linkType="Reference"&gt;627651&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The Orange-book listed &lt;ulink linkID="IN2148108" linkType="Patent"&gt;US-05202128&lt;/ulink&gt; provided exclusivity for Kadian, and expired in April 2010.&lt;/para&gt;&lt;para&gt;In November 2011, &lt;ulink linkID="21717" linkType="Company"&gt;Watson Pharmaceuticals&lt;/ulink&gt; received FDA approval for its generic version of Kadian capsules; shipment of the product began immediately [&lt;ulink linkID="1238663" linkType="Reference"&gt;1238663&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, Actavis launched an authorized generic version of Kadian [&lt;ulink linkID="1275067" linkType="Reference"&gt;1275067&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Impax launched a generic version in December 2016 [&lt;ulink linkID="1887872" linkType="Reference"&gt;1887872&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;REGULATORY INFORMATIONThe US&lt;/subtitle&gt;By June 1996, Kadian had been filed for approval in the US by former US licensee &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; [&lt;ulink linkID="190141" linkType="Reference"&gt;190141&lt;/ulink&gt;]. In July 1996, the product was approved in the US for the management of moderate-to-severe chronic pain where treatment with an opioid analgesic is indicated for more than a few days, and subsequently launched later that year by licensee Zeneca  [&lt;ulink linkID="213178" linkType="Reference"&gt;213178&lt;/ulink&gt;]. In April 2007, the FDA approved a 10 mg Kadian capsule formulation; at that time, Kadian was available as 10, 20, 30 , 50 , 60, 80, 100 and 200 mg capsules [&lt;ulink linkID="660932" linkType="Reference"&gt;660932&lt;/ulink&gt;], [&lt;ulink linkID="736207" linkType="Reference"&gt;736207&lt;/ulink&gt;], [&lt;ulink linkID="769801" linkType="Reference"&gt;769801&lt;/ulink&gt;], [&lt;ulink linkID="786647" linkType="Reference"&gt;786647&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By June 1995, Kadian had been filed for approval in the UK by licensee Sanofi Winthrop [&lt;ulink linkID="190141" linkType="Reference"&gt;190141&lt;/ulink&gt;]; by February 1996,  approval had been granted in the UK [&lt;ulink linkID="200351" linkType="Reference"&gt;200351&lt;/ulink&gt;]; it is presumed that launch occurred shortly following approval. By October 1999, the product had been launched in most EU countries by licensee GSK under the trade name Kapanol [&lt;ulink linkID="349169" linkType="Reference"&gt;349169&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In October 1999, approval was granted in Japan [&lt;ulink linkID="349169" linkType="Reference"&gt;349169&lt;/ulink&gt;], [&lt;ulink linkID="352716" linkType="Reference"&gt;352716&lt;/ulink&gt;]; in November 1999, the product was launched by Japanese licensee &lt;ulink linkID="15606" linkType="Company"&gt;Dainippon&lt;/ulink&gt; (now &lt;ulink linkID="1017117" linkType="Company"&gt;Dainippon Sumitomo&lt;/ulink&gt;) [&lt;ulink linkID="393513" linkType="Reference"&gt;393513&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By June 1995, the product had been filed for approval in Canada [&lt;ulink linkID="190141" linkType="Reference"&gt;190141&lt;/ulink&gt;]; by February 1996,  approval had been granted in Canada [&lt;ulink linkID="200351" linkType="Reference"&gt;200351&lt;/ulink&gt;]; by December 1999, Kadian had been launched in Canada [&lt;ulink linkID="352716" linkType="Reference"&gt;352716&lt;/ulink&gt;]. By December 2006, licensee &lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt; was marketing Kadian in Canada [&lt;ulink linkID="1267580" linkType="Reference"&gt;1267580&lt;/ulink&gt;], [&lt;ulink linkID="1219603" linkType="Reference"&gt;1219603&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In February 2019, the Therapeutic Goods Administration (TGA) has approved Kadian low dose 10 and 20 mg capsules in Australia, for the treatment of dyspnea. At that time, an application to the Pharmaceutical Benefits Advisory Committee was made to expand the Pharmaceutical Benefits Scheme (PBS) reimbursement of drug to include  the new treatment of chronic breathlessness [&lt;ulink linkID="2121030" linkType="Reference"&gt;2121030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 1994, the product was launched in Australia for the management of cancer-related pain under the trade name Kapanol  by  licensee GSK [&lt;ulink linkID="190141" linkType="Reference"&gt;190141&lt;/ulink&gt;], [&lt;ulink linkID="1221466" linkType="Reference"&gt;1221466&lt;/ulink&gt;]. In April 1999, the Australian label was expanded for the relief of chronic pain unresponsive to non-narcotic analgesia [&lt;ulink linkID="1219579" linkType="Reference"&gt;1219579&lt;/ulink&gt;], [&lt;ulink linkID="1221469" linkType="Reference"&gt;1221469&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 1999, licensee GSK had also launched the product in New Zealand [&lt;ulink linkID="349169" linkType="Reference"&gt;349169&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;Based upon a review of studies carried out by Alpharma on the interaction of Kadian and alcohol, the FDA had indicated by March 2007 that the  label did not require any further modifications [&lt;ulink linkID="815395" linkType="Reference"&gt;815395&lt;/ulink&gt;]. The US label has a black box warning regarding abuse, life-threatening respiratory depression, and accidental ingestion [&lt;ulink linkID="660932" linkType="Reference"&gt;660932&lt;/ulink&gt;]; the warning also includes neonatal opioid withdrawal syndrome and interactions with alcohol [&lt;ulink linkID="660932" linkType="Reference"&gt;660932&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In February 2007, results from a  phase IV study showed the pharmacokinetics of the long-acting opioid were not significantly affected by the consumption of alcohol. The study was carried out on request from the FDA [&lt;ulink linkID="765048" linkType="Reference"&gt;765048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PREMARKETING STUIDES&lt;/subtitle&gt;In May 2019, an open-label, non inferiority, randomized, parallel assignment, controlled, phase III trial (&lt;ulink linkID="380477" linkType="Protocol"&gt;NCT03948464&lt;/ulink&gt;; BCCSU-002; pRESTO) was planned to initiate in July 2019 in Canada to evaluate and compare  the relative effectiveness, safety and acceptability of slow release oral morphine (SROM) vs methadone for the second line oral treatment for opioid use disorder in outpatient clinical settings. The primary end point was measuring of opioid use by the overall proportion of opioid free urine drug screens during the 24 weeks of active treatment (excluding the assigned therapy and it's metabolites) with missing samples defined as being positive for opioids at 24 weeks. At that time, the trial was expected to complete in January 2024 [&lt;ulink linkID="2152266" linkType="Reference"&gt;2152266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Pain data from a double-blind, controlled, trial assessing the safety and efficacy of Kadian in cancer patients showed that Kadian once daily was similar to the same total dose of morphine administered in divided doses with respect to pain relief, use of rescue medication, patient and investigator global assessment and quality of sleep [&lt;ulink linkID="1219579" linkType="Reference"&gt;1219579&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from a randomized, multicenter, open-label, parallel-group trial comparing the efficacy and tolerability of Kadian once daily with morphine sulfate controlled-release tablets (MST) in patients (n = 165) with severe chronic pain (73.5% non-malignant and 26.5% malignant) were reported, which demonstrated that significantly more patients treated with Kadian (73.0%) achieved an adequate analgesia compared with MST (55.5%) [&lt;ulink linkID="1219579" linkType="Reference"&gt;1219579&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Dyspnea&lt;/subtitle&gt;By November 2014, phase II efficacy trials had been conducted by &lt;ulink linkID="20576" linkType="Company"&gt;Flinders University&lt;/ulink&gt; with sustained-release morphone for the treatment of refractory dyspnea, which showed evidence of a reduction in the incidence of breathlessness. At that time, Mayne licensed rights to clinical studies conducted by Flinders University for dyspnoea. Also at that time, a phase III study for dyspnoea was ongoing and data were expected in 2015 [&lt;ulink linkID="1616332" linkType="Reference"&gt;1616332&lt;/ulink&gt;]. In August 2016, a phase III, multi-center, double-blind, placebo-controlled, parallel-arm, dose-increment, randomized trial (&lt;ulink linkID="256778" linkType="Protocol"&gt;NCT02720822&lt;/ulink&gt;; 030/15; BEAMS) conducted by Flinders University began in Australia to assess regular, low-dose sustained-release morphone  in patients (expected n = 171) with chronic refractory breathlessness. At that time, the trial was expected to complete in December 2017. In August 2018, recruitment was ongoing and the trial was expected to complete in June 2019 [&lt;ulink linkID="2065514" linkType="Reference"&gt;2065514&lt;/ulink&gt;]. In February 2019, data demonstrated that the drug reduced debilitating breathlessness symptoms [&lt;ulink linkID="2121030" linkType="Reference"&gt;2121030&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2014, Mayne signed an agreement with Flinder University to license exclusive worldwide rights to past, present and key future clinical studies conducted by Flinders University on the treatment of dyspnea and related intellectual property [&lt;ulink linkID="1616332" linkType="Reference"&gt;1616332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1037040">Mayne Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2400">Dyspnea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-02-19T00:00:00.000Z</StatusDate><Source id="2121030" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037040">Mayne Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-01T00:00:00.000Z</StatusDate><Source id="1531295" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-01T00:00:00.000Z</StatusDate><Source id="1483450" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-11-29T00:00:00.000Z</StatusDate><Source id="393513" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037040">Mayne Pharma Group Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-05-14T00:00:00.000Z</StatusDate><Source id="2152266" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16969">Zeneca Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="973466" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15138">Bristol-Myers Squibb (Pty) Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-02-27T00:00:00.000Z</StatusDate><Source id="200351" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-30T00:00:00.000Z</StatusDate><Source id="973460" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26660">Sanofi Winthrop Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-30T00:00:00.000Z</StatusDate><Source id="973460" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-30T00:00:00.000Z</StatusDate><Source id="973460" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24932">Faulding &amp; Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-12T00:00:00.000Z</StatusDate><Source id="973466" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24932">Faulding &amp; Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-12T00:00:00.000Z</StatusDate><Source id="973466" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14008">Alpharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-30T00:00:00.000Z</StatusDate><Source id="973460" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="27069">GlaxoSmithKline Australia</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-08-01T00:00:00.000Z</StatusDate><Source id="190141" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-10-27T00:00:00.000Z</StatusDate><Source id="349169" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015171">Actavis Group HF</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-30T00:00:00.000Z</StatusDate><Source id="973460" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16969">Zeneca Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-02-27T00:00:00.000Z</StatusDate><Source id="200351" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16969">Zeneca Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-07-05T00:00:00.000Z</StatusDate><Source id="213178" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037040">Mayne Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2400">Dyspnea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-11-27T00:00:00.000Z</StatusDate><Source id="1616332" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-29T00:00:00.000Z</StatusDate><Source id="1219603" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-10-27T00:00:00.000Z</StatusDate><Source id="349169" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26660">Sanofi Winthrop Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-12-31T00:00:00.000Z</StatusDate><Source id="200351" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037040">Mayne Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2400">Dyspnea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-11-27T00:00:00.000Z</StatusDate><Source id="1616332" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037040">Mayne Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2400">Dyspnea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-02-19T00:00:00.000Z</StatusDate><Source id="2121030" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><Source id="187426" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-11-01T00:00:00.000Z</StatusDate><Source id="349169" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-05-27T00:00:00.000Z</StatusDate><Source id="326203" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15138">Bristol-Myers Squibb (Pty) Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-06-01T00:00:00.000Z</StatusDate><Source id="190141" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24932">Faulding &amp; Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-02-01T00:00:00.000Z</StatusDate><Source id="200351" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24932">Faulding &amp; Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-06-01T00:00:00.000Z</StatusDate><Source id="190141" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16969">Zeneca Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-11-11T00:00:00.000Z</StatusDate><Source id="224876" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16453">Glaxo Group Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><Source id="349169" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16453">Glaxo Group Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><Source id="179207" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16453">Glaxo Group Ltd</Company><Country id="XI">South East Asia</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><Source id="179207" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24932">Faulding &amp; Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-12-13T00:00:00.000Z</StatusDate><Source id="352716" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24932">Faulding &amp; Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-07-05T00:00:00.000Z</StatusDate><Source id="213178" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16453">Glaxo Group Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><Source id="179207" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14008">Alpharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-12T00:00:00.000Z</StatusDate><Source id="973466" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26660">Sanofi Winthrop Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-02-01T00:00:00.000Z</StatusDate><Source id="200351" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26660">Sanofi Winthrop Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-06-01T00:00:00.000Z</StatusDate><Source id="190141" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01361"><Name>Opioid receptor mu</Name><SwissprotNumbers><Swissprot>P33535</Swissprot><Swissprot>P35372</Swissprot><Swissprot>P42866</Swissprot><Swissprot>P79350</Swissprot><Swissprot>P97266</Swissprot><Swissprot>Q5IS39</Swissprot><Swissprot>Q95247</Swissprot><Swissprot>Q95M54</Swissprot><Swissprot>Q9MYW9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1012208">Zuellig Pharma Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1037040">Mayne Pharma Group Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>10</CountTotal></Company><Company><Company id="1081794">Palliative Care Clinical Studies Collaborative</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1088700">Allergan plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15872">Eisai Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="20268">Sumitomo Chemical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20576">Flinders University of South Australia</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>5</CountActive><CountInactive>0</CountInactive><CountTotal>5</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O</Smiles><Smiles>CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.OS(=O)(=O)O</Smiles><Smiles>CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.O.O.O.O.O.OS(=O)(=O)O</Smiles></StructureSmiles><Deals><Deal id="111367" title="MGI Pharma to copromote Alpharma's Kadian in the US for cancer pain"></Deal><Deal id="119054" title="Actavis to market Kadian from King Pharmaceuticals  "></Deal><Deal id="119937" title="Bristol-Myers Squibb to distribute Faulding's Kadian in the US"></Deal><Deal id="124327" title="Alpharma to acquire US rights to Faulding's Kadian "></Deal><Deal id="124329" title="Zeneca to market Faulding's Kadian in the US"></Deal><Deal id="124333" title="Glaxo Wellcome to market Faulding's oral morphine in New Zealand, Europe, South-East Asia and China, excluding in Australia "></Deal><Deal id="124335" title="Sanofi Winthrop to market Faulding's oral morphine in the UK and Eire"></Deal><Deal id="124337" title="Dainippon to license Japanese rights to Faulding's oral morphine"></Deal><Deal id="151864" title="Mayne Pharma to license Flinders University's IP for the development of Kapanol against dyspnea worldwide "></Deal><Deal id="151865" title="Zuellig Pharma to distribute Mayne Pharma's Kapanol in Thailand "></Deal><Deal id="173237" title="Mayne acquires GSK's Kapanol (morphine sulfate) modified release oral opioid for pain in Australia"></Deal><Deal id="239014" title="Manufacture of Kadian long-acting opiod product"></Deal><Deal id="253668" title="PaCCSC to conduct research for Mayne's Kapanol repurposing drug for breathlessness symptoms "></Deal></Deals><PatentFamilies><PatentFamily id="110497" number="JP-2001048778" title="Fat and oil containing sustained-release suppository"></PatentFamily><PatentFamily id="149224" number="WO-2011154414" title="Diversion-resistant microgranules and microtablets"></PatentFamily><PatentFamily id="1588021" number="WO-2006124890" title="Morphine sulphate formulations"></PatentFamily><PatentFamily id="1754630" number="WO-2007109104" title="Modified release formulations containing drug-ion exchange resin complexes"></PatentFamily><PatentFamily id="1857754" number="WO-2009079518" title="Pharmaceutical composition"></PatentFamily><PatentFamily id="186933" number="JP-2003004735" title="The immunoassay and measurement kit of morphine"></PatentFamily><PatentFamily id="1987699" number="WO-09531972" title="Powder-Layered Oral Dosage Forms"></PatentFamily><PatentFamily id="2054345" number="WO-09925329" title="Use of sulphinyl benzhydryl derivatives for treating drug-induced sleepiness."></PatentFamily><PatentFamily id="2236394" number="EP-00377518" title="Sustained release pharmaceutical composition"></PatentFamily><PatentFamily id="2756039" number="WO-2014091437" title="Oral form, comprising immediate-release coated particles of at least one active compound that are grinding-resistant"></PatentFamily><PatentFamily id="278765" number="US-08158156" title="Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist"></PatentFamily><PatentFamily id="2799734" number="WO-2014140095" title="Injectable morphine formulations"></PatentFamily><PatentFamily id="30011" number="WO-2008139170" title="Transdermal and transmucosal drug delivery enhancers"></PatentFamily><PatentFamily id="3023670" number="WO-2011141241" title="Alcohol-resistant oral pharmaceutical form"></PatentFamily><PatentFamily id="3039675" number="US-09145420" title="Crystalline forms of morphine sulfate"></PatentFamily><PatentFamily id="3140295" number="US-20160058755" title="Pharmaceutical composition"></PatentFamily><PatentFamily id="3668869" number="WO-2017087373" title="Modified release abuse deterrent tablet"></PatentFamily><PatentFamily id="4256963" number="WO-2018204163" title="An opioid for use to reduce and/or treat drug addiction"></PatentFamily><PatentFamily id="49926" number="WO-03015758" title="Sustained release micropellets and process for producing the same"></PatentFamily><PatentFamily id="552790" number="WO-2007149438" title="Pharmaceutical compositions"></PatentFamily><PatentFamily id="596246" number="WO-2010141505" title="Abuse-resistant delivery systems"></PatentFamily><PatentFamily id="643566" number="WO-00074659" title="Morphine sulphate microgranules, method for preparing same and compositions containing same"></PatentFamily><PatentFamily id="924321" number="JP-2001048809" title="Polyglycerol behenic-acid ester containing sustained-release suppository"></PatentFamily><PatentFamily id="985653" number="WO-09920255" title="Oral morphine multiparticulate formulation."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayne Pharma Group Ltd" id="1037040"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>